Showing 161-170 of 333 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Effects of Volagidemab on Glucagon Rescue from Insulin-Induced Hypoglycemia | REMD Biotherapeutics | Dung Thai | Improving Lives | 30-June-2023 to 29-June-2026 | $672,000.00 |
| Hybrid Closed Loop Therapy for Beta Cell Preservation in New Onset Type 1 Diabetes (CLVer): Extension Study (CLVerEX) | Regents of the University of Minnesota | Antoinette Moran | Cures | 01-April-2023 to 31-March-2026 | $1,739,442.00 |
| Mechanistic Etiologies Underlying the Impact of Verapamil to Preserve β Cell Function in Type 1 diabetes | Regents of the University of Minnesota | Antoinette Moran | Cures | 01-September-2024 to 31-August-2026 | $643,946.00 |
| Growing Beta Cell Replacement in T1D by Tolerizing Stem Cell-Derived Islets | Regents of the University of Minnesota | Bernhard Hering | Cures | 01-August-2025 to 31-July-2027 | $688,430.02 |
| Preclinical development of a combinatorial therapy with a humanized antibody to serpinB13 in type 1 diabetes | Regents of the University of Minnesota | Jan Czyzyk | Cures | 01-June-2022 to 31-May-2025 | $765,000.00 |
| Employing PD-L1-Modified Biomaterials to Induce Islet Allograft Tolerance Following Perihepatic Transplantation in Nonhuman Primates | Regents of the University of Minnesota | Melanie Graham | Cures | 01-April-2025 to 31-March-2027 | $918,744.88 |
| Determining how frequent infections alter autoreactive T-cell fates and type 1 diabetes risk | Regents of the University of Minnesota | Zachary Shaheen | Cures | 01-June-2024 to 31-May-2025 | $199,890.00 |
| Novel mechanisms of ketoacidosis with SGLT2 inhibitors in type 1 diabetes | Regents of the University of Michigan | Jennifer Schaub | Improving Lives | 01-April-2025 to 31-March-2026 | $200,000.00 |
| Cell capture scaffold to monitor islet transplant rejection | Regents of the University of Michigan | Lonnie Shea | Cures | 01-September-2023 to 28-February-2026 | $600,000.00 |
| Identifying pharmaceuticals for enhancing metabolic maturity of stem cell derived islets | Regents of the University of Michigan | Lonnie Shea | Cures | 01-December-2024 to 30-November-2027 | $1,125,000.00 |